Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Baseline Frequency of Inflammatory Cxcl9 Expressing Tumor-Associated Macrophages Predicts Response to Avelumab (anti-PDL-1) Treatment

ABSTRACT: Baseline Frequency of Inflammatory Cxcl9 Expressing Tumor-Associated Macrophages Predicts Response to Avelumab (anti-PDL-1) Treatment

PROVIDER: PRJNA634259 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11823820.fastq.gz	Fastqsanger.gz
	SRR11823821.fastq.gz	Fastqsanger.gz
	SRR11823822.fastq.gz	Fastqsanger.gz
	SRR11823823.fastq.gz	Fastqsanger.gz
	SRR11823824.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 60

Similar Datasets

Baseline Frequency of Inflammatory Cxcl9 Expressing Tumor-Associated Macrophages Predicts Response to Avelumab (anti-PDL-1) Treatment

Project description:scRNA-Sequencing of CD45+ TILs taken from a single tumor of a bilateral pair prior to avelumab treatment

2020-05-22 | GSE150970 | GEO

PHASE IB STUDY OF AVELUMAB WITH RADIOTHERAPY IN PATIENTS WITH LEPTOMENINGEAL DISEASE

Project description:A phase IB, single-arm, non-randomized study to establish the safety of the PDL-1 inhibitor Avelumab with radiotherapy in patients with leptomeningeal disease (LMDz) from metastatic melanoma, lung cancer, and breast cancer. We hypothesize 1) systemic Avelumab will activate peripheral T cells and, with whole-brain radiotherapy (to induce blood-brain-barrier breakdown and stimulate antigen expression), significantly increase the number and activation status of T cells that migrate into the cerebrospinal fluid (CSF), with an Inflammatory CSF cytokine profile, in patients with LMDz; 2) this treatment regime is safe and tolerated without significant toxicities and will improve overall survival compared to historical controls; and 3) point estimates (with confidence intervals) can be derived using CSF measurements, toxicities, and clinical benefit to estimate sample sizes/schedules for an expanded Recommended Phase II Study.

2025-09-05 | GSE299082 | GEO

OFCD (Occulofciocardiodental) patient's PDL (peridontal ligament cells) and Healthy control PDL cells

Project description:Transcriptional profiling of mouse embryonic stem cells comparing Mutant PDL cells and healthy PDL cells to study Radiculomegaly (excessive dental root elongation) Two-condition experiment, Mutant vs. Healthy PDL cells, technological triplicate

2022-03-18 | GSE198708 | GEO

Gene expression of mice PDL , WT and Mkx KO (10 weeks and 4 weeks)

Project description:The periodontal ligament (PDL), which connects the teeth to the alveolar bone, is essential for periodontal tissue homeostasis. Although the significance of the PDL is recognized, molecular mechanisms underlying PDL function are not well-known. We report that Mohawk homeobox (Mkx), a tendon-specific transcription factor, regulates PDL homeostasis by preventing its degeneration. Mkx is expressed in the mouse PDL at the age of 10 weeks and 12 months. In Mkx-/- mice, age-dependent expansion of the PDL at the maxillary 1st molar (M1) furcation area was observed. Transmission electron microscopy (TEM) revealed that Mkx-/- mice presented collagen fibril degeneration in PDL with age, while the collagen fibril diameter gradually increased in Mkx+/+ mice. PDL cells lost their shape in Mkx-/- mice, suggesting changes in PDL properties. Microarray and quantitative polymerase chain reaction (qPCR) analyses of Mkx-/- PDL revealed an increase in osteogenic gene expression and no change in PDL- and inflammatory-related gene expression. Additionally, COL1A1 and COL1A2 were upregulated in Mkx-overexpressing human PDL fibroblasts, whereas osteogenic genes were downregulated. Our results indicate that Mkx prevents PDL degeneration by regulating osteogenesis. Mohawk transcription factor is essential for homeostasis of the periodontal ligament by regulating osteogenic changes with age.

2017-01-17 | GSE92331 | GEO

OFCD (Occulofciocardiodental) patient's PDL (peridontal ligament cells) and Healthy control PDL cells

Project description:OFCD (Occulofciocardiodental) patient's PDL (peridontal ligament cells) and Healthy control PDL cells

| PRJNA816513 | ENA

Transcriptomic profiling of peripheral blood cells in HPV-associated carcinoma patients receiving combined valproic acid and avelumab

Project description:We recruited 39 samples of metastatic HPV-associated carcinoma patients before and after immunotherapy (Combined Valproic acid + Avelumab). Based on the best overall response by iRECIST criteria, we stratified patients into Responders (iCCR, iCPR, iSD) and Non-responders (Clinically progressive, iCPD, iUPD). We analyzed the transcript differential expression in two groups (Rs vs. NRs) before (Baseline) and after therapy (EP) to understand the differences between the two groups in each time point and in time points (C1, C2, EP) compared to C0 for each group to check the changes related to therapy.

2023-09-14 | GSE229014 | GEO

Combination therapy of NHS-IL12 and avelumab enhances antitumor efficacy in preclinical cancer models

Project description:Nanostring gene expression profiling of 24 BALB/c mice bearing EMT-6 tumors under avelumab and NHS-muIL12 mono and combination therapies.

2017-12-20 | GSE93192 | GEO

PDL cellS from human deciduous and permanent teeth LC-MS/MS

Project description:Physiological functions of periodontal ligament (PDL) include anchorage, force absorption,and proprioceptive information. Despite the knowledge about biology of PDL cells, there is a lack of information regarding the molecular signature of permanent (PermPDL) and deciduous (DecPDL) PDL tissues. The present study was designed to characterize the membrane proteome of DecPDL and PermPDL primary cells (n=6) by a label-free quantitative proteome.

2018-12-14 | PXD010226 | Pride

Avelumab for People With Recurrent Respiratory Papillomatosis

Project description:Avelumab for People With Recurrent Respiratory Papillomatosis

| PRJNA713423 | ENA

Avelumab for People With Recurrent Respiratory Papillomatosis

Project description:Avelumab for People With Recurrent Respiratory Papillomatosis

| PRJNA713424 | ENA